"乡村振兴 大有可为"专场招聘会 为推动高校毕业生投身乡村振兴事业，国家大学生就业服务平台将推出"乡村振兴 大有可为"专场 招聘会。活动聚焦农林、文旅等多个乡村振兴相关领域，汇聚优质岗位资源，积极引导毕业生深入乡 村、服务基层，在投身乡村建设中实现个人价值，预计提供岗位约3万个，活动将持续至2026年1月31 日。 2026届全国高校本科毕业生专场招聘会 根据教育部2026届高校毕业生"寒假促就业暖心行动"部署，为充分利用寒假窗口期，全力促进高校 毕业生高质量充分就业，国家大学生就业服务平台正式推出"寒假促就业暖心行动"专题栏目，整合各类 招聘会信息、各地各高校招聘活动安排、"宏志助航"线上培训课程及实习岗位资源等多项就业服务，旨 在进一步汇聚就业岗位资源、提升就业服务质量，促进更多毕业生尽早就业。 行动期间，国家大学生就业服务平台将陆续上线"'一带一路'区域面向高校毕业生网上招聘会""汽车 行业面向2026届高校毕业生专场招聘会""'乡村振兴 大有可为'专场招聘会"等15场重点招聘活动，聚焦 重点区域、重点行业和重点群体，为毕业生与用人单位搭建高效对接平台。 活动参与方式：高校毕业生和用人单位可通过"寒假促 ...

同标的指数中唯一挂钩的ET "ONLY" 标签指截至2025年12月28日,市场上跟踪该标的指数的 一只ETF。"低费率"标签指管理费率0.15%/年,托管费率 注!:"该指数"指各上述基金产品具体跟踪的指数。数据来自Wind,指数涨跌幅截至2026年1月22日收盘,滚动市盈旱,估值分位截至2026年1月 21日。滚动市盘单=总市值/ 近四个季度归属母公司股东的净利润,该估值指标和企业盈利紧密相关、适用于盈利相对稳定且受周期影响较小的 行业。估值分位指该指数历史上滚动市盈率低于当前滚动市盈率的时间占比,估值分位低表示相对便宜。估值分位区间为指数发布日/可查询估值 数据记录日起至2026年1月21日。恒生港股通创新药指数2023年7月10日发布:中证港股通医药卫生综合指数2017年6月23日发布,可查询估值记录 日为2017年9月29日起;中证创新药产业指数2019年4月22日发布;中证生物科技主题指数2015年8月26日发布;沪深300医药卫生指数2007年7月2 日发布。 医药板块今日集体回调，截至收盘，恒生港股通创新药指数下跌1.4%，中证港股通医药卫生综合指 数、中证创新药产业指数均下跌1.1%，中证生 ...

东方证券指出，科创企业在资本开支周期下处于强景气周期。国内流动性整体充裕，资金向高景气赛道 集中，结构性机会居多。 中银国际指出，作为"十五五"开局之年，科技自立自强与先进制造有望成为核心主线。科技领域需转向 体系化配置，覆盖关键核心技术、高端制造等多方向；先进制造向多层次体系升级，布局未来产业。 1月20日，科创创业ETF（588360）回调超2.5%，科创板块结构性机会显著，回调或可布局。 科创创业ETF（588360）跟踪的是科创创业50指数（931643），单日涨跌幅限制达20%，该指数从科创 板和创业板中选取市值较大、流动性较好的50只上市公司证券作为指数样本，以反映市场中科技创新相 关上市公司证券的整体表现。指数样本覆盖了信息技术、医药卫生等多个行业，旨在突出企业的创新能 力和成长潜力。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the news is that the Medical ETF (512170) has experienced a decline of 1.61%, with the latest price at 0.366 yuan and a turnover rate of 2.25% [1] - The Medical ETF closely tracks the CSI Medical Index, which includes companies involved in medical devices, medical services, and medical information technology [1] - The latest scale of the Medical ETF is 26.117 billion yuan, with a total of 70.245 billion shares, indicating an increase of 524 million yuan in fund size over the past month [1] Group 2 - As of the previous trading day, the Medical ETF (512170) saw a net inflow of 26.1418 million yuan [2] - The top ten weighted stocks in the CSI Medical Index include WuXi AppTec, Mindray Medical, United Imaging Healthcare, Aier Eye Hospital, Kanglong Chemical, Tigermed, Lepu Medical, Yuyue Medical, New Industry, and Meinian Onehealth [2]

- The report discusses the market's potential to stabilize and the possibility of a rebound after a period of consolidation, aligning with previous predictions[1][8] - From a wave theory perspective, the market's recent surge can be seen as a major wave, with the current adjustment potentially being a fourth wave correction[8] - The 20-day moving average has historically provided support during similar adjustments since April of the previous year[8] - Volume analysis indicates that significant volume reduction during a bull market correction can signal the end of the adjustment phase, with historical data suggesting that a reduction to 55% of the recent peak volume may indicate a nearing end to the correction[8] - The report includes an industry four-wheel drive model, highlighting recent trading opportunities in sectors such as technology and healthcare, with specific signals and corresponding ETFs listed for each opportunity[16]

Group 1 - The core viewpoint of the article highlights the resilience of the technology sector, driven by liquidity easing, policy support, and high industry prosperity [1] - The AI hardware sector is benefiting from a global technology cycle, with marginal profit growth (ΔG) showing no signs of a turning point, indicating continued strength [1] - AI applications are transitioning from computational infrastructure to scenario realization, accelerating commercialization due to policy guidance, demand release, and increased capital investment [1] Group 2 - New themes emerging from the 14th Five-Year Plan, such as commercial aerospace and brain-computer interfaces, have the potential to become new mainlines in the industry [1] - The cyclical industries are performing actively due to improvements in PPI and supportive policies against internal competition, creating a dual growth pattern of technology and cyclical sectors [1] - The ChiNext Index ETF Guotai (589630) tracks the ChiNext Index (000680), which has a daily price fluctuation limit of 20% and covers approximately 97% of the market capitalization with over 500 constituent stocks [1]

Group 1 - The pharmaceutical sector led the market today, with significant gains in medical services and CRO concepts, as evidenced by the rise in various indices [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index and the CSI Biotech Theme Index both increased by 1.9%, while the CSI 300 Pharmaceutical Health Index rose by 1.7% [1] - Active trading was noted in related ETFs, with the Hong Kong Stock Connect Innovative Drug ETF (159316) and the Pharmaceutical ETF (512010) achieving transaction volumes of 820 million and 1.09 billion respectively, indicating increased market activity [1] Group 2 - According to Zhongtai Securities, multiple factors are driving a gradual recovery in demand for CRO and CDMO within the pharmaceutical sector, alongside a continuous supply-side clearance over the past three years [1] - The sector is expected to experience a "Davis Double Play," where both profitability and valuation are anticipated to improve [1]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing active performance, with significant gains in key stocks and positive forecasts for companies like WuXi AppTec, indicating a strong recovery in the CRO and CDMO demand side, alongside a potential "Davis Double Play" for the sector [1] Group 1: Market Performance - As of 15:00 on January 13, the Hang Seng Biotechnology Index and the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index both rose by 1.0% [1] - Notable stock performances include WuXi AppTec rising over 7%, WuXi Biologics increasing over 5%, and Weigao Group and WuXi AppTec's subsidiary rising over 3% [1] Group 2: Company Forecasts - WuXi AppTec announced a profit forecast for the fiscal year 2025, expecting a net profit attributable to shareholders of 19.151 billion yuan, representing a year-on-year growth of approximately 102.65% [1] - Institutions predict that WuXi AppTec's order growth will continue to outpace global peers in 2026, indicating strong market positioning [1] Group 3: Industry Insights - According to Zhongtai Securities, multiple factors are driving a gradual recovery in the demand side for CRO and CDMO within the pharmaceutical sector, combined with a supply-side clearance over the past three years [1] - The Hang Seng Biotechnology Index focuses on leading biotechnology firms within the Hong Kong Stock Connect, covering various sub-sectors including biotechnology, pharmaceuticals, and medical devices [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index targets leading companies in the pharmaceutical and health industry, encompassing medical devices and innovative drugs [1] Group 4: Investment Tools - The E Fund Hang Seng Biotechnology ETF (159105) and the E Fund Hong Kong Stock Connect Pharmaceutical ETF (513200) track the aforementioned indices, providing diversified investment tools for investors to capitalize on opportunities in the pharmaceutical industry [2]

Group 1 - The pharmaceutical and biotechnology industry is entering the latter stage of quality improvement and expansion in centralized procurement, with a focus on both pricing mechanisms and quality supervision [1] - The national centralized procurement has covered a total of 435 varieties, with the eleventh batch focusing on 55 clinically mature drugs, aiming to ensure clinical accessibility and standard consistency through institutional innovation [1] - As procurement rules continue to optimize and pricing mechanisms become more reasonable, leading domestic companies are expected to achieve market share growth and structural expansion through compliance and innovation capabilities [1] Group 2 - The medical insurance fund's revenue growth has turned positive year-on-year, with a projected increase of 2.92% in income and 0.51% in expenditure from January to November 2025, indicating stable overall fund operation [1] - Ongoing medical reforms are expected to advance from inpatient DRGs to outpatient APGs, with the construction of a multi-tiered payment system for innovative drugs in commercial insurance, shifting the focus of medical insurance management from "scale" to "value" [1] - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies involved in medical devices, medical services, and medical information technology to reflect the overall performance of the medical theme-related securities [1]

中央纪委国家监委驻国家卫生健康委员会纪检监察组工作人员在山东省淄博市，调研了解医保基金 管理突出问题整治情况。 驻国家卫生健康委员会纪检监察组供图 习近平总书记强调，要把整治群众身边不正之风和腐败问题作为重要任务常态化地抓。中央纪委国家监 委驻国家卫生健康委员会纪检监察组坚决落实党中央部署要求，紧扣群众急难愁盼问题，以更强决心、 更大力度、更实举措深化正风肃纪反腐，切实维护人民群众健康权益。 有依靠、群众购药更可及、异地就医更便捷、医保经办更高效。推动加强科普宣传，维护市场秩序，保 障群众生命健康。 明确方法路径，推动医药领域群众身边不正之风和腐败问题整治走深走实 这是厚植我们党的执政根基的必然要求。习近平总书记反复强调"江山就是人民、人民就是江山""民心 是最大的政治""人民群众最痛恨腐败现象，我们就必须坚定不移反对腐败"。群众对身边的不正之风和 腐败问题感受最直接、最痛恨，有些问题看似小事，实则关乎民心，解决不好就会影响群众福祉和党的 形象，就会不断侵蚀党的执政根基。深化整治群众身边不正之风和腐败问题，正是通过严查人民痛恨之 事、狠刹百姓憎恶之风，解决群众急难愁盼问题，使群众得实惠、使我们党得民心。实践充 ...